lilly glp-1 Lilly's KwikPen Delivers Month of Zepbound in One Device Lilly's diabetes drug ahead of

Regional Analysis North America is leading the GLP-1 Receptor Agonist Market North America dominated the market with the highest revenue share of 49.7% owing to the high prevalence of both type 2 diabetes and obesity, coupled with a well-established healthcare infrastructure and favorable reimbursement policies

Goldman Sachs Research estimates that GLP-1 obesity drug prescriptions could reach 30 million Americans by 2028 if coverage barriers are resolved, representing USD 150+ billion in additional annual market potential beyond current diabetes-only prescribing

van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M

Why GLP-1 users need targeted supplementation GLP-1 receptor agonists work by mimicking a natural hormone that regulates appetite, blood sugar, and gastric emptying

A combined effect that is bigger than just decreasing calories is thought to be at play when looking at the effects of activating the GLP-1 receptor.[ref] In overweight adults aged 45+, a 4-year-long study using semaglutide for weight loss also prevented HbA1c from rising over time, which was seen in the placebo arm

Both products are tailored to meet the specific needs of individuals taking GLP-1 medications and support their overall nutritional health